Quantcast

Latest Immunosuppressants Stories

2014-12-11 16:24:58

First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif. and LONDON, Dec.

2014-12-09 08:28:43

FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS, Dec.

2014-12-02 00:21:56

- Update on complete remissions with personalized cell therapy CTL019 in patients with relapsed/refractory acute lymphoblastic leukemia EAST HANOVER, N.J., Dec.

2014-12-01 08:29:53

DALLAS, December 1, 2014 /PRNewswire/ -- ReportsnReports.com adds EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023 market research on the autoimmune

2014-11-25 16:27:52

Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo THOUSAND OAKS, Calif. and LONDON, Nov.

2014-11-24 16:24:42

However, Platform Injectables Continue to Represent the Majority of Recent MS Prescriptions, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.

2014-11-24 12:26:31

U.S. Court of Appeals for the Federal Circuit Concurrently Affirms Denial of Antares Pharma's Motion to Prohibit the Marketing of Rasuvo CHICAGO, Nov.

2014-11-24 08:27:22

Right the Wrong Campaign seeks to educate Canadians on how a government approved drug left them with severe birth defects that challenge their lives to this day MONTREAL, Nov.


Word of the Day
deuteragonist
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.
Related